| Trial ID: | L6813 |
| Source ID: | NCT05596747
|
| Associated Drug: |
Ly3209590
|
| Title: |
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3209590|DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, Number of Participants with One or More AEs and SAEs Considered by the Investigator to be Related to Study Drug Administration, Baseline up to Week 12|Incidence and Severity of Hypoglycemia, Incidence and Severity of Hypoglycemia, Baseline up to Week 12 | Secondary: Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose, PD: Change from Baseline in Fasting Plasma Glucose, Baseline through Week 6|PD: Change from Baseline in 7-Point Glucose, PD: Change from Baseline in 7-Point Glucose, Baseline through Week 6
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
31
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2022-11-30
|
| Completion Date: |
2023-10-10
|
| Results First Posted: |
|
| Last Update Posted: |
2024-01-02
|
| Locations: |
Tianjin Medical University General Hospital, Tianjin, Tianjin, 300052, China
|
| URL: |
https://clinicaltrials.gov/show/NCT05596747
|
